Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6Francesconi, Lenise P.a,b,c; Victorino, André T.a,c; Salah, Iarsan A.c; Cordova, Victor H.S.c; Dias da Rosa, Eduardab; Oliveira, Larissab; Jacobus, Raquel V.M.c; Belmonte-de-Abreu, Paulo S.a,c; Ceresér, Keila M.a,b,cInternational Clinical Psychopharmacology: March 2019 - Volume 34 - Issue 2 - p 84–88 doi: 10.1097/YIC.0000000000000241 SHORT COMMUNICATIONS Buy Abstract Author InformationAuthors Article MetricsMetrics The present study sought to assess biomarkers of inflammation in stable patients with schizophrenia (SZ) on clozapine therapy. We recruited 60 outpatients with SZ and 60 healthy controls, matched for sex and age. Compared with controls, patients had significantly increased concentrations of interleukin-6 and tumor necrosis factor-α. Interestingly, patients on simvastatin had lower interleukin-6 levels compared with patients not on simvastatin and controls. This study corroborated previous evidence for increased inflammatory biomarkers in SZ and detected a potential anti-inflammatory action of simvastatin in patients with a clinical diagnosis of SZ on clozapine therapy. aPostgraduate Program in Psychiatry and Behavioral Sciences, Universidade Federal do Rio Grande do Sul bLaboratory of Molecular Psychiatry cSchizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil Correspondence to Keila M. Ceresér, PhD, Postgraduate Program in Psychiatry and Behavioral Sciences, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2350, Porto Alegre 90035-903, Rio Grande do Sul, Brazil Tel: +55 51 3359 8845; fax: +55 51 3359 8846; e-mail: email@example.com Received July 30, 2018 Accepted October 9, 2018 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.